BioSpace News Archive

Medivir AB announces that the first patient has been enrolled in a phase I study to investigate the safety and tolerability of a combination treatment of birinapant and radiation therapy in patients with recurrent Head and Neck Squamous Cell Carcinoma.

AgraFlora Organics International Inc. applauds its exclusive CBD sports partner, the Toronto Wolfpack RLFC’s promotion to the 2020 RLF Super League competition; an accomplishment that positions the TWP in the highest tier of English rugby league, boasting international broadcast reach to over 250,000,000 homes.

West Pharmaceutical Services, Inc. announced that it will release third-quarter 2019 financial results before the market opens on Thursday, October 24, 2019, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time.

ProQR Therapeutics N.V. announced positive top-line results from the PQ-110-001 study, a Phase 1/2 dose range finding, first-in-human trial of sepofarsen (QR-110) in patients with Leber’s congenital amaurosis 10 (LCA10) due to the p.Cys998X mutation in the CEP290 gene.

BOCAhealth with its ‘body fluids manager’ receives the Pharma Trend 2019 “Most Innovative Product” award in the startups category.

Constellation Pharmaceuticals, Inc. announced that the Company will present updates of clinical data from the MANIFEST clinical trial of CPI-0610 in oral and poster presentations at the American Society of Hematology (ASH) annual meeting on December 9.

Company to Host Conference Call on Wednesday, November 6, 2019 at 1:30 p.m. PT / 4:30 p.m. ET

Enlivex Therapeutics Ltd. (Nasdaq:ENLV), a clinical-stage immunotherapy company, today announced today that the European and Int’l Shock Societies selected, for an oral presentation, “Pathogen- and damage-associated molecular patterns are immune modified by apoptotic cell adjuvant therapy for acute sepsis in a cecal ligation and puncture mice model, and avoids multi-organ failure and improves survival” to be presented at the XVIIIth Congress of the European Shock Society and IXth Congres

Rheostat Therapeutics, an emerging biopharmaceutical company pursuing novel approaches for the treatment of debilitating neurodegenerative diseases by preserving neurons, today announced the company has changed its name to Caraway Therapeutics.

Aptose Biosciences Inc. announced that William G. Rice, Ph.D., Chairman, President and CEO, and Jotin Marango, M.D., Ph.D., Senior VP and CBO, will participate at the 5th International Conference on Acute Myeloid Leukemia “Molecular and Translational” Advances in Biology and Treatment, and present preclinical data for CG-806, its oral, first-in-class pan-FLT3/pan-BTK inhibitor, in a poster presentation on October 24th, 2019 in Estoril, Portugal.